01 / DISCOVERY
Identify distinctive biology
Focus on proteins and peptides with strong mechanistic relevance to cell injury, repair, homeostasis and disease.
About TRIM-edicine
From discovery to therapeutic opportunity
TRIM-edicine is a privately held biotechnology company focused on translating distinctive protein and peptide biology into approaches for tissue repair, regenerative medicine, age-related dysfunction and oncology.
Our company
Built around biology with broad therapeutic relevance
TRIM-edicine's historical portfolio spans membrane repair, tissue protection, cellular homeostasis, aging biology and peptide therapeutics for cancer.
TRIM-edicine is engaged in the development of novel biopharmaceutical products addressing important unmet medical needs.
The company's historical work has included applications in tissue repair, ischemia/reperfusion injury, dermal wounds, oral health, sports medicine, muscular dystrophy, age-related dysfunction and oncology.
Research and development has emphasized proof-of-concept studies, translational validation, intellectual property development and partnerships that can move promising discoveries toward therapeutic applications.
How we work
A translational path from mechanism to development
The legacy company model combines scientific discovery with development partnerships rather than treating basic biology and commercialization as separate activities.
02 / TRANSLATION
Build proof of concept
Develop therapeutic approaches, validation studies and preclinical evidence around the most promising biological mechanisms.
03 / PARTNERSHIP
Advance with collaborators
Engage academic, government and industry collaborators, investors, development partners and potential licensees.
The previous About page contained time-specific statements dating back to 2015. Version 2 intentionally avoids presenting those historical claims as current facts until company status and patent information are verified.